NO953832L - Sykliske forbindelser som kan anvendes som inhibitorer for blodplateglykoprotein IIb/IIIa - Google Patents

Sykliske forbindelser som kan anvendes som inhibitorer for blodplateglykoprotein IIb/IIIa

Info

Publication number
NO953832L
NO953832L NO953832A NO953832A NO953832L NO 953832 L NO953832 L NO 953832L NO 953832 A NO953832 A NO 953832A NO 953832 A NO953832 A NO 953832A NO 953832 L NO953832 L NO 953832L
Authority
NO
Norway
Prior art keywords
cyclic compounds
platelet
glycoprotein iib
iiia
inhibitors
Prior art date
Application number
NO953832A
Other languages
English (en)
Other versions
NO953832D0 (no
Inventor
William Frank Degrado
Sharon Anne Jackson
Shaker Ahmed Mousa
Anju Parthasarathy
Michael Sworin
Maria Rafalski
Original Assignee
Du Pont Merck Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Merck Pharma filed Critical Du Pont Merck Pharma
Publication of NO953832D0 publication Critical patent/NO953832D0/no
Publication of NO953832L publication Critical patent/NO953832L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Denne oppfinnelsen vedrører nye, sykliske forbindelser som inneholder karbosykliske ringsystemer, som kan anvendes som antagonister for blod- plateglykoprotein Ilb/IIIa-komplekset, farmasøytiske preparater som inneholder slike sykliske forbindelser sammen med eller uten andre terapeutiske midler, og fremgangsmåter for anvendelse av disse forbindelsene sammen med eller uten andre terapeutiske midler, for inhiberingen av blodplateaggregasjon, som trombolytika og/eller for behand- ling av andre tromboemboliske sykdom- mer. Denne oppfinnelsen vedrører også fremgangsmåter for anvendelse av de sykliske forbindelsene ifølge oppfin- nelsen i kombinasjon med antikoagula- sjonsmidler, slik som warfarin eller heparin, eller ytterligere anti- blodplatemidler, slik som aspirin, piroxicam eller ticlopidin, eller trom- bininhibitorer, slik som borpeptider, hirudin eller argatroban, eller trom- bolytiske midler, slik som vevsplas- minogenaktivator, anistreplase, urokin- ase eller streptokinase, eller kombina- sjoner derav, til behandlingen av trom- boemboliske sykdommer.
NO953832A 1993-03-29 1995-09-28 Sykliske forbindelser som kan anvendes som inhibitorer for blodplateglykoprotein IIb/IIIa NO953832L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3844893A 1993-03-29 1993-03-29
PCT/US1994/003223 WO1994022910A1 (en) 1993-03-29 1994-03-28 CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa

Publications (2)

Publication Number Publication Date
NO953832D0 NO953832D0 (no) 1995-09-28
NO953832L true NO953832L (no) 1995-11-28

Family

ID=21900014

Family Applications (1)

Application Number Title Priority Date Filing Date
NO953832A NO953832L (no) 1993-03-29 1995-09-28 Sykliske forbindelser som kan anvendes som inhibitorer for blodplateglykoprotein IIb/IIIa

Country Status (10)

Country Link
EP (1) EP0691987A1 (no)
JP (1) JPH08508498A (no)
AU (1) AU6415894A (no)
CA (1) CA2159070A1 (no)
FI (1) FI954556A0 (no)
HU (1) HUT72896A (no)
NO (1) NO953832L (no)
NZ (1) NZ263456A (no)
PL (1) PL310896A1 (no)
WO (1) WO1994022910A1 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ263455A (en) * 1993-03-29 1997-10-24 Du Pont Merck Pharma Synthesis of platelet glycoprotein iib/iiia inhibitors
US5879657A (en) * 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
DE69731763T3 (de) * 1996-11-27 2010-12-30 Aventis Pharmaceuticals Inc. Pharmazeutische Zusammenstellung, die eine Verbindung mit Anti-Xa-Eigenschaften und eine Verbindung, die ein Plakettenaggregationsantagonist ist, enthalten
US6010911A (en) * 1997-04-30 2000-01-04 Medtronic, Inc. Apparatus for performing a heparin-independent high sensitivity platelet function evaluation technique
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
GB0623607D0 (en) 2006-11-27 2007-01-03 Haemostatix Ltd Tissue adhesive
WO2008095063A1 (en) 2007-01-31 2008-08-07 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
US11673914B2 (en) 2009-11-10 2023-06-13 Allegro Pharmaceuticals, LLC Peptide therapies for reduction of macular thickening
CN105106934A (zh) 2009-11-10 2015-12-02 急速制药公司 用于抑制细胞粘附至rgd结合位点或引导诊断剂或治疗剂至rgd结合位点的组合物和方法
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
EP2707036A4 (en) 2011-05-09 2015-03-18 Allegro Pharmaceuticals Inc INTEGRIN RECEPTOR ANTAGONISTS AND METHOD FOR THEIR USE
AU2012326026B2 (en) 2011-10-18 2017-04-13 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
CN112500466B (zh) 2012-02-15 2022-05-03 艾瑞朗医疗公司 拟肽大环化合物
WO2013123267A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
AU2013337388B2 (en) 2012-11-01 2018-08-02 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
SG10201902598VA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
KR20170129879A (ko) 2015-03-20 2017-11-27 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
EP3347372A4 (en) 2015-09-10 2019-09-04 Aileron Therapeutics, Inc. PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2636066B1 (fr) * 1988-09-02 1991-10-25 Centre Nat Rech Scient Derives de cyclopeptides, utilisables comme inhibiteurs selectifs vis-a-vis de proteases a serine active
US5384309A (en) * 1989-07-17 1995-01-24 Genentech, Inc. Cyclized peptides and their use as platelet aggregation inhibitors
AU6470590A (en) * 1989-10-23 1991-04-26 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
IL103252A (en) * 1991-09-30 1997-03-18 Du Pont Merck Pharma CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Also Published As

Publication number Publication date
FI954556A (fi) 1995-09-26
FI954556A0 (fi) 1995-09-26
EP0691987A1 (en) 1996-01-17
PL310896A1 (en) 1996-01-08
NZ263456A (en) 1996-11-26
WO1994022910A1 (en) 1994-10-13
NO953832D0 (no) 1995-09-28
CA2159070A1 (en) 1994-10-13
HU9502832D0 (en) 1995-11-28
HUT72896A (en) 1996-06-28
AU6415894A (en) 1994-10-24
JPH08508498A (ja) 1996-09-10

Similar Documents

Publication Publication Date Title
NO953832L (no) Sykliske forbindelser som kan anvendes som inhibitorer for blodplateglykoprotein IIb/IIIa
Walsh et al. Contributions of human platelets to the proteolytic activation of blood coagulation factors XII and XI
Refino et al. A variant of t-PA (T103N, KHRR 296-299 AAAA) that, by bolus, has increased potency and decreased systemic activation of plasminogen
DK36991A (da) Vaevsplasminoaktivator-(t-pa)-variant med zymogene eller fibrinspecifikke eller plasmakoagel-specifikke egenskaber, fremgangsmaade til fremstilling deraf, dna-sekvens, som koder for varianten, replicerbar udtrykkelsesvektor for denne og vaertsceller transformeret med vektoren
EA199700452A1 (ru) Новые изоксазолиновые и изоксазольные антагонисты рецептора фибриногена
DK0401508T3 (da) Proteaseinhibitorer, fremgangsmåde til deres fremstilling samt lægemidler med indhold deraf
Suntravat et al. cDNA cloning of a snake venom metalloproteinase from the eastern diamondback rattlesnake (Crotalus adamanteus), and the expression of its disintegrin domain with anti-platelet effects
Remold et al. Enhancement of migration inhibitory factor activity by plasma esterase inhibitors
Da Silva et al. Anti-platelet effect of cumanastatin 1, a disintegrin isolated from venom of South American Crotalus rattlesnake
Collen Thrombolytic therapy
Korhonen Fibrinolytic and procoagulant activities of Yersinia pestis and Salmonella enterica
Komiyama et al. Protection from anthrax toxin-mediated killing of macrophages by the combined effects of furin inhibitors and chloroquine
ES2120713T3 (es) Compuestos de isoxazolinas utiles como antagonistas de receptores del fibrinogeno.
NO941561L (no) Bifunksjonelle urokinasevarianter med forbedrede fibrinolytiske egenskaper og trombinhemmende virkning
ES2337879T3 (es) Procedimiento de dosificacion de la fibrina soluble.
Furukawa et al. Factor X converting and thrombin-like activities of Bothrops jararaca snake venom
Chu et al. Purification and characterization of a novel fibrinolytic enzyme from Whitmania pigra Whitman
Ribeiro de Queiroz et al. Purification and characterization of BmooAi: a new toxin from Bothrops moojeni snake venom that inhibits platelet aggregation
BRPI0409557A (pt) proteìna inibidora recombinante de calicreìna, seqüência de dna, vetor de expressão, célula hospedeira, composição farmacêutica e seu uso, método de produção de proteìna inibidora recombinante de calicreìna e kit de diagnóstico para detecção de calicreìna
Walker et al. The inhibition of tissue activator and urokinase by human plasma
Amel et al. Purification and characterization of a new serine protease (VLCII) isolated from Vipera lebetina venom: Its role in hemostasis
Bisacchi Anticoagulants, antithrombotics, and hemostatics
Markland et al. Applications of snake toxins in biomedicine
Bang Leeches, snakes, ticks, and vampire bats in today's cardiovascular drug development.
Matsushima et al. Activation of fibrinolysis with the protease from Dermatophagoides farinae